 | | Vol. 10.23 – 15 June, 2022 |
| |
|
|
| Scientists showed that pregnancy-induced post-translational antibody modification enabled protection against the prototypical intracellular pathogen Listeria monocytogenes.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors investigated T and B cell immunity against B.1.1.529 in triple mRNA vaccinated healthcare workers with different SARS-CoV-2 infection histories.
[Science] |
|
|
|
| Researchers explored the neurobiological effects of respiratory SARS-CoV-2 infection and found white-matter-selective microglial reactivity in mice and humans.
[Cell] |
|
|
|
| The authors recruited convalescent COVID-19 children and adults to define their circulating memory SARS-CoV-2-specific CD4+ and CD8+ T cells prior to vaccination. They analyzed epitope-specific T cells directly ex vivo using seven HLA class-I and class-II tetramers presenting SARS-CoV-2 epitopes, together with Spike-specific B cells.
[Immunity] |
|
|
|
| Investigators evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study.
[Science Translational Medicine] |
|
|
|
| Scientists assessed the efficacy of therapeutic monoclonal antibodies against Omicron variant sublineage BA.1 variants in Syrian hamsters.
[Nature Microbiology] |
|
|
|
| The authors investigated the long-term antibody persistence in previously infected subjects and the extent of the antibody-mediated protection against B.1, B.1.617.2, and BA.1 variants in unvaccinated subjects previously infected, vaccinated naïve, and vaccinated previously infected subjects.
[Genome Medicine] |
|
|
|
| Researchers developed a proteomic screen to identify retrograde cargo proteins of the endosomal SNX-BAR sorting complex promoting exit 1 (ESCPE-1) and used this to identify Neuropilin-1, a recently characterized host factor for SARS-CoV-2 infection, as a cargo directly bound and trafficked by ESCPE-1.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists performed an in silico analysis to identify host microRNA targeting ACE2, TMPRSS2, and/or RAB14, all genes known to participate in the viral entry and replication.
[Molecular Therapy-Nucleic Acids] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Researchers reported in vivo B cell engineering using two adeno-associated viral vectors, with one coding for Staphylococcus aureus Cas9 and the other for 3BNC117, an anti-HIV broadly neutralizing antibody.
[Nature Biotechnology] |
|
|
|
| Investigators described how variants of the plasmid-encoded donor outer membrane (OM) protein TraN cooperated with distinct OM receptors in recipients to mediate mating pair stabilization and efficient DNA transfer.
[Nature Microbiology] |
|
|
|
| The authors reported that overexpression of Schlafen-5 (SLFN5) inhibited HIV-1 replication and reduced viral mRNA levels, whereas depletion of endogenous SLFN5 promoted HIV-1 replication.
[Nucleic Acids Research] |
|
|
|
| Mycobacterium tuberculosis and the EST12 protein negatively regulated the expression of a key long non-coding RNA, named lnc-EST12, in mouse macrophages by activating the JAK2-STAT5a signaling pathway.
[Cellular & Molecular Immunology] |
|
|
|
|
| Scientists delineate how SARS-CoV-2 manipulates diverse cell death and cell autophagy for its benefits, which is simultaneously involved in the occurrence and progression of COVID-19, aiming to provide a reasonable basis for the existing interventions and further development of novel therapies.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators review six cases of SARS-CoV-2 that resulted in cancer remission, simultaneously highlighting the strengths and the unique challenges of oncolytic virotherapy.
[Molecular Therapy-Oncolytics] |
|
|
|
|
| Codagenix Inc. announced that it has completed dosing of its Phase I clinical trial to evaluate CodaVaxâ„¢-H1N1, a universal, live-attenuated influenza vaccine.
[Codagenix, Inc.] |
|
|
|
| Clover Biopharmaceuticals, Ltd. announced the first participants have been dosed in a Phase III study evaluating the safety and immunogenicity of Clover’s SCB-2019 vaccine candidate as a COVID-19 booster in individuals who previously vaccinated with CoronaVac™, Comirnaty®, or Vaxzevria®.
[Clover Biopharmaceuticals, Ltd.] |
|
|
|
| PureTech Health’s long COVID trial has come up short. The drug candidate failed to help patients with the condition walk farther, prompting the company to drop plans for further studies in the indication.
[Fierce Biotech] |
|
|
|
|
| September 7 -11, 2022
Woods Hole, Massachusetts, United States |
|
|
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | Temple University – Philadelphia, Pennsylvania, United States |
|
|
|
| | National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| | The Walter and Eliza Hall Institute – Parkville, Australia |
|
|
|
| | Nationwide Children’s Hospital – Columbus, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
